CONRIG PHARMA ApS
Nøgletal
- Afkastningsgrad
- -151 %
- Egenkapitalforrentning
- –
- Likviditetsgrad
- 100 %
- Soliditetsgrad
- 0 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | -98.936 |
Driftsresultat | -98.936 |
Finansielle omkostninger | 546 |
Årets resultat | -95.786 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 0 |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 21.140 |
Kortfristede aktiver | 65.518 |
Aktiver i alt | 65.518 |
Egenkapital | 0 |
Forpligtelser i alt | 65.518 |
Kortfristede forpligtelser | 65.518 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Andre kortfristede tilgodehavender | 4.199 |
Leverandørgæld | 19.125 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 123.802 |
Overført resultat | -123.802 |
Højdepunkter fra årsrapporten
Forretning og udvikling
Description of key activities of the companyThe company's principal activity is developing new medical drugs and other related operations.
Significant changes in the company's activities and financial mattersThere have been no significant changes in activities and financial matters.
The gross loss for the year totals DKK -98.936 against DKK -92.016 last year. Profit or loss from ordinary activities after tax totals DKK -95.786 against DKK -100.217 last year. Management considers the net profit or loss for the year satisfactory.…
Risici og væsentlige forhold
Events occurring after the end of the financial yearNo Events have occurring subsequebt to the balance sheet date, which would have material impact on
the financial positition of the company.
Forpligtelser og sikkerhedsstillelser
3.Contractual obligations and contingencies, etc.
Contingent assetsThe company has not recognized a deferred tax asset of t.DKK 709 due to uncertainty regarding
for future usage.
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger